This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Biotech Sector Weekly Rewind

BOSTON ( TheStreet) -- The biotech sector in rewind for the week ending Oct. 8, 2010:

Sanofi-Aventis (SNY) launched a $69-a-share hostile tender offer for Genzyme (GENZ) after efforts failed to reach a takeover agreement with Genzyme management on more friendly terms. Then, both companies bickered over whether Sanofi offered $80-a-share, or not. Next week, the scheduling of the muay thai bout between Sanofi's Chris Viehbacher and Genzyme's Henri Termeer. My money is on Viehbacher.

ImmunoGen's (IMGN) TDM-1 Looks Strong at ESMO

The FDA extended the review period for Salix Pharmaceuticals' (SLXP) Xifaxan by three months to March 7, 2011. Salix is seeking to expand Xifaxan's approved label to include the treatment of non-constipation irritable bowel syndrome. The original FDA drug approval decision date was Dec. 7.

Cell Therapeutics (CTIC) CEO Jim Bianco sold 400,000 shares of company stock at 37-38 cents a share.

This week's Biotech Stock Mailbag: Cyclacel Pharmaceuticals (CYCC), Seattle Genetics (SGEN), Anylam Pharmaceuticals (ALNY), Adventrx Pharmaceuticals (ANX), Celldex Therapeutics (CLDX).

(Not so) fun fact: $1.7 billion in funds exited the healthcare sector in the first nine months of the year, while $15.2 billion in funds were sunk into all equity funds during the same time period, according to BioCentury. (Hat tip: ISI Group biotech analyst Mark Schoenebaum.)

The week's top-performing sector stocks: Anthera Pharmaceuticals (ANTH) (+25.4%), Idenix Pharmaceuticals (IDIX) (+24.8%), Neurocrine BioSciences (NBIX) (+22.9%), Nymox Pharmaceuticals (NYMX) (+21.9%) and Nile Therapeutics (NLTX) (+21%).

Notable financings: Celgene (CELG) raises $1.25 billion through a corporate bond sale; Cyclacel Pharmaceuticals nets $14 million in a private placement of stock and warrants.

Notable financing for all the wrong reasons: Spherix (SPEX - Get Report) pulls the trigger on an intraday, Rodman and Renshaw-led preferred stock and warrants sale just hours after releasing questionable phase III diabetes data.

October's FDA drug approval-palooza starts off on wrong foot with complete response letters issued to Hospira (HSP) for the pain reliever Dyloject and Human Genome Sciences (HGSI) for its hepatitis C drug Zalbin.

More FDA drug approval decisions coming next week: Alexa Pharmaceuticals (ALXA - Get Report) and Jazz Pharmaceuticals (JAZZ - Get Report) on Monday night, Alkermes (ALKS) on Tuesday night.

InterMune (ITMN) sells hepatitis C drug danoprevir to Roche, makes all-or-nothing bet on its lung drug pirfenidone.

As chief executive, David Nance drove Introgen Therapeutics into bankruptcy and disgrace, but his best pal Texas Gov. Rick Perry continues to supply Nance with taxpayer funds. The Dallas Morning News has all the illuminating details.

Onyx Pharma (ONXX) delays multiple myeloma drug approval filing.

The week's worst-performing sector stocks: Spherix (SPEX - Get Report) (-22.6%), NuPath (PATH) (-18.7%), SCOLR Pharma (DDD) (-17.1%), Immucor (BLUD) (-17.1%) and AspenBio Pharma (APPY) (-16.9%).

Wait… I thought Pfizer (PFE) was going to buy Generex Biotechnology (GNBT)? Rumor mill says Pfizer reportedly interested in acquiring experimental diabetes pill from India's Biocon Ltd. (More here from @lisamjarvis.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ALXA $2.11 2.90%
ITMN $73.89 -0.03%
JAZZ $173.51 -0.96%
IDIX $24.50 0.20%
SPEX $0.95 2.09%


DOW 18,189.13 -25.29 -0.14%
S&P 500 2,112.13 +1.39 0.07%
NASDAQ 4,986.8380 -1.0520 -0.02%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs